17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00098488
Recruitment Status : Terminated
First Posted : December 8, 2004
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : April 2008
  Study Completion Date : No date given